Evidence for SH2 domain-containing 5′ -Inositol phosphatase-2 (SHIP2) contributing to a lymphatic dysfunction

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Agollah, Germaine D ^a,b   Gonzalez Garay, Manuel L ^a   Rasmussen, John C ^a   Tan, I Chih ^a   Aldrich, Melissa B ^a   Darne, Chinmay ^a   Fife, Caroline E ^c   Guilliod, Renie ^c   Maus, Erik A ^c   King, Philip D ^d   Sevick Muraca, Eva M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c MEMORIAL HERMANN HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SHIP2; PROTEIN TYROSINE PHOSPHATASE SHP; REGULATOR PROTEIN; UNCLASSIFIED DRUG; HGF PROTEIN, HUMAN; INPPL1 PROTEIN, HUMAN; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PHOSPHATASE; SCATTER FACTOR;

ADULT; ARTICLE; CASE REPORT; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE IMAGING; GENE; GENETIC CODE; HEREDITARY LYMPHEDEMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INPPL1 GENE; LYMPH VESSEL ENDOTHELIUM; LYMPHATIC SYSTEM DISEASE; MULTIGENE FAMILY; MUTATIONAL ANALYSIS; NEAR INFRARED FLUORESCENCE LYMPHATIC IMAGING; NEXT GENERATION SEQUENCING; NUCLEOTIDE SEQUENCE; PHENOTYPE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; AGED; CELL CULTURE; CHEMISTRY; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; LYMPHEDEMA; MALE; MIDDLE AGED; PATHOLOGY; POINT MUTATION; PROCEDURES; SRC HOMOLOGY DOMAIN;

ADULT; AGED; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; HEPATOCYTE GROWTH FACTOR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHEDEMA; MALE; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; OPTICAL IMAGING; PHOSPHORIC MONOESTER HYDROLASES; POINT MUTATION; SEQUENCE ANALYSIS, DNA; SRC HOMOLOGY DOMAINS;

EID: 84911453582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112548     Document Type: Article

References (59)

1. Alitalo K (2011) The lymphatic vasculature in disease. Nat Med 17: 1371-1380.
2. Karpanen T, Alitalo K (2008) Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 3: 367-397.
3. Tammela T, Alitalo K (2010) Lymphangiogenesis: Molecular mechanisms and future promise. Cell 140: 460-476.
4. Mortimer PS, Rockson SG (2014) New developments in clinical aspects of lymphatic disease. J Clin Invest 124: 915-921.
5. Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, et al. (2000) Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 67: 1382-1388.
6. Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, et al. (2003) Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet 72: 1470-1478.
7. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, et al. (2000) Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 25: 153-159.
8. Alders M, Hogan BM, Gjini E, Salehi F, Al-Gazali L, et al. (2009) Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat Genet 41: 1272-1274.
9. Ostergaard P, Simpson MA, Mendola A, Vasudevan P, Connell FC, et al. (2012) Mutations in KIF11 cause autosomal-dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy. Am J Hum Genet 90: 356-362.
10. Ferrell RE, Baty CJ, Kimak MA, Karlsson JM, Lawrence EC, et al. (2010) GJC2 missense mutations cause human lymphedema. Am J Hum Genet 86: 943-948.
11. Finegold DN, Baty CJ, Knickelbein KZ, Perschke S, Noon SE, et al. (2012) Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment. Clin Cancer Res 18: 2382-2390.
12. Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, et al. (2011) Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 43: 929-931.
13. Burrows PE, Gonzalez-Garay ML, Rasmussen JC, Aldrich MB, Guilliod R, et al. (2013) Lymphatic abnormalities are associated with RASA1 gene mutations in mouse and man. Proc Natl Acad Sci U S A 110: 8621-8626.
14. Gordon K, Schulte D, Brice G, Simpson MA, Roukens MG, et al. (2013) Mutation in vascular endothelial growth factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant milroy-like primary lymphedema. Circ Res 112: 956-960.
15. Kurek KC, Luks VL, Ayturk UM, Alomari AI, Fishman SJ, et al. (2012) Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet 90: 1108-1115.
16. Hoey SE, Eastwood D, Monsell F, Kangesu L, Harper JI, et al. (2008) Histopathological features of Proteus syndrome. Clin Exp Dermatol 33: 234-238.
17. Brouillard P, Boon L, Vikkula M (2014) Genetics of lymphatic anomalies. J Clin Invest 124: 898-904.
18. Mouta-Bellum C, Kirov A, Miceli-Libby L, Mancini ML, Petrova TV, et al. (2009) Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha. Dev Dyn 238: 2670-2679.
19. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, et al. (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.
20. Zhou F, Chang Z, Zhang L, Hong YK, Shen B, et al. (2010) Akt/Protein kinase B is required for lymphatic network formation, remodeling, and valve development. Am J Pathol 177: 2124-2133.
21. Suwa A, Kurama T, Shimokawa T (2010) SHIP2 and its involvement in various diseases. Expert Opin Ther Targets 14: 727-737.
22. Prasad NK, Decker SJ (2005) SH2-containing 5′-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor. J Biol Chem 280: 13129-13136.
23. Giuriato S, Pesesse X, Bodin S, Sasaki T, Viala C, et al. (2003) SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3,4,5-trisphosphate levels. Biochem J 376: 199-207.
24. Deneubourg L, Vanderwinden JM, Erneux C (2010) Regulation of SHIP2 function through plasma membrane interaction. Adv Enzyme Regul 50: 262-271.
25. Rasmussen JC, Tan IC, Marshall MV, Adams KE, Kwon S, et al. (2010) Human Lymphatic Architecture and Dynamic Transport Imaged Using Nearinfrared Fluorescence. Transl Oncol 3: 362-372.
26. Rasmussen JC, Tan IC, Marshall MV, Fife CE, Sevick-Muraca EM (2009) Lymphatic imaging in humans with near-infrared fluorescence. Curr Opin Biotechnol 20: 74-82.
27. Roach JC, Glusman G, Smit AF, Huff CD, Hubley R, et al. (2010) Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 328: 636-639.
28. Finegold DN, Schacht V, Kimak MA, Lawrence EC, Foeldi E, et al. (2008) HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol 6: 65-68.
29. Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, et al. (2010) Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer 116: 5138-5149.
30. Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M (2005) Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 24: 2885-2895.
31. Saito Y, Nakagami H, Morishita R, Takami Y, Kikuchi Y, et al. (2006) Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesis. Circulation 114: 1177-1184.
32. Sevick-Muraca EM, King PD (2013) Lymphatic vessel abnormalities arising from disorders of Ras signal transduction. Trends Cardiovasc Med.
33. Koch A, Mancini A, El Bounkari O, Tamura T (2005) The SH2-domiancontaining inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading. Oncogene 24: 3436-3447.
34. Prasad NK, Tandon M, Badve S, Snyder PW, Nakshatri H (2008) Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis 29: 25-34.
35. Lapinski PE, Kwon S, Lubeck BA, Wilkinson JE, Srinivasan RS, et al. (2012) RASA1 maintains the lymphatic vasculature in a quiescent functional state in mice. J Clin Invest 122: 733-747.
36. Ichise T, Yoshida N, Ichise H (2010) H-, N- and Kras cooperatively regulate lymphatic vessel growth by modulating VEGFR3 expression in lymphatic endothelial cells in mice. Development 137: 1003-1013.
37. Deng Y, Atri D, Eichmann A, Simons M (2013) Endothelial ERK signaling controls lymphatic fate specification. J Clin Invest 123: 1202-1215.
38. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, et al. (2006) Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 3: 995-1000.
39. Mihara M, Hara H, Araki J, Kikuchi K, Narushima M, et al. (2012) Indocyanine green (ICG) lymphography is superior to lymphoscintigraphy for diagnostic imaging of early lymphedema of the upper limbs. PLoS One 7: e38182.
40. Sevick-Muraca EM, Kwon S, Rasmussen JC (2014) Emerging lymphatic imaging technologies for mouse and man. J Clin Invest 124: 905-914.
41. Mihara M, Murai N, Hayashi Y, Hara H, Iida T, et al. (2012) Using indocyanine green fluorescent lymphography and lymphatic-venous anastomosis for cancer-related lymphedema. Ann Vasc Surg 26: 278 e271-276.
42. Mendola A, Schlogel MJ, Ghalamkarpour A, Irrthum A, Nguyen HL, et al. (2013) Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema. Mol Syndromol 4: 257-266.
43. Tridandapani S, Kelley T, Cooney D, Pradhan M, Coggeshall KM (1997) Negative signaling in B cells: SHIP Grbs Shc. Immunol Today 18: 424-427.
44. Tamir I, Stolpa JC, Helgason CD, Nakamura K, Bruhns P, et al. (2000) The RasGAP-binding protein p62dok is a mediator of inhibitory FcgammaRIIB signals in B cells. Immunity 12: 347-358.
45. Kagawa S, Sasaoka T, Yaguchi S, Ishihara H, Tsuneki H, et al. (2005) Impact of SRC homology 2-containing inositol 59-phosphatase 2 gene polymorphisms detected in a Japanese population on insulin signaling. J Clin Endocrinol Metab 90: 2911-2919.
46. Readinger JA, Mueller KL, Venegas AM, Horai R, Schwartzberg PL (2009) Tec kinases regulate T-lymphocyte development and function: new insights into the roles of Itk and Rlk/Txk. Immunol Rev 228: 93-114.
47. Cagnol S, Chambard JC (2010) ERK and cell death: mechanisms of ERKinduced cell death-apoptosis, autophagy and senescence. FEBS J 277: 2-21.
48. Moro L, Arbini AA, Marra E, Greco M (2007) Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2. Int J Oncol 30: 217-224.
49. Liu X, Ma B, Malik AB, Tang H, Yang T, et al. (2012) Bidirectional regulation of neutrophil migration by mitogen-activated protein kinases. Nat Immunol 13: 457-464.
50. Huber C, Faqeih EA, Bartholdi D, Bole-Feysot C, Borochowitz Z, et al. (2013) Exome sequencing identifies INPPL1 mutations as a cause of opsismodysplasia. Am J Hum Genet 92: 144-149.
51. Below JE, Earl DL, Shively KM, McMillin MJ, Smith JD, et al. (2013) Wholegenome analysis reveals that mutations in inositol polyphosphate phosphataselike 1 cause opsismodysplasia. Am J Hum Genet 92: 137-143.
52. Clement S, Krause U, Desmedt F, Tanti JF, Behrends J, et al. (2001) The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409: 92-97.
53. Sleeman MW, Wortley KE, Lai KM, Gowen LC, Kintner J, et al. (2005) Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat Med 11: 199-205.
54. Ishida S, Funakoshi A, Miyasaka K, Shimokata H, Ando F, et al. (2006) Association of SH-2 containing inositol 59-phosphatase 2 gene polymorphisms and hyperglycemia. Pancreas 33: 63-67.
55. Kaisaki PJ, Delepine M, Woon PY, Sebag-Montefiore L, Wilder SP, et al. (2004) Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome. Diabetes 53: 1900-1904.
56. Zhou XP, Marsh DJ, Hampel H, Mulliken JB, Gimm O, et al. (2000) Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet 9: 765-768.
57. Lin S, Kim J, Lee MJ, Roche L, Yang NL, et al. (2012) Prospective transcriptomic pathway analysis of human lymphatic vascular insufficiency:identification and validation of a circulating biomarker panel. PLoS One 7:e52021.
58. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, et al. (1994) A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77: 261-271.
59. Coso S, Zeng Y, Opeskin K, Williams ED (2012) Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis. PLoS One 7: e39558.